Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 6/20 | 0.49 |
| ▸ | RET | P07949 | 2/20 | 0.46 |
| ▸ | CDK8 | P49336 | 5/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | RAF1 | P04049 | 6/20 | 0.44 |
| ▸ | BRAF | P15056 | 2/20 | 0.44 |
| ▸ | CCNC | P24863 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | PLK4 | O00444 | 1/20 | 0.42 |
| ▸ | CIT | O14578 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | MUSK | O15146 | 1/20 | 0.42 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3545330 | 1.00 | KDR (0.49) | KDRRETCDK8NAMPTRAF1 | |
| SCHEMBL3538984 | 0.87 | KDR (0.46) | KDRRETCDK8NAMPTRAF1 | |
| SCHEMBL3538987 | 0.87 | KDR (0.46) | KDRRETCDK8NAMPTRAF1 | |
| SCHEMBL3548740 | 0.84 | KDR (0.49) | KDRRETCDK8NAMPTRAF1 | |
| SCHEMBL3548737 | 0.84 | KDR (0.49) | KDRRETCDK8NAMPTRAF1 | |
| SCHEMBL3549413 | 0.84 | KDR (0.46) | KDRRETCDK8NAMPTRAF1 | |
| SCHEMBL3549408 | 0.84 | KDR (0.46) | KDRRETCDK8NAMPTRAF1 | |
| SCHEMBL3547742 | 0.83 | KDR (0.49) | KDRRETCDK8NAMPTRAF1 | |
| SCHEMBL3547747 | 0.83 | KDR (0.49) | KDRRETCDK8NAMPTRAF1 | |
| SCHEMBL3543475 | 0.83 | KDR (0.45) | KDRRETCDK8NAMPTRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652041-B2 | 4-[4-(3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl)phenoxy]pyridino-2-carboxamido: N-methyl-4-[4-(3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl)phenoxy]pyridine-2-carboxamide: Raf-kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-01-26 | — | — | US | claimed |
| US-7820697-B2 | Compositions and method for reducing TNFα levels | CELGENE CORPORATION (US) | 2010-10-26 | — | — | US | disclosed |
| US-7652041-B2 | 4-[4-(3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl)phenoxy]pyridino-2-carboxamido: N-methyl-4-[4-(3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl)phenoxy]pyridine-2-carboxamide: Raf-kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-7652041-B2 | 4-[4-(3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl)phenoxy]pyridino-2-carboxamido: N-methyl-4-[4-(3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl)phenoxy]pyridine-2-carboxamide: Raf-kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-7652041-B2 | 4-[4-(3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl)phenoxy]pyridino-2-carboxamido: N-methyl-4-[4-(3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propyl)phenoxy]pyridine-2-carboxamide: Raf-kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20080287496-A1 | 1-Oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels | CELGENE CORPORATION | 2008-11-20 | — | — | US | disclosed |
| US-20060160803-A1 | Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | US | disclosed |
| US-20060030592-A1 | I-Oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels | CELGENE CORPORATION | 2006-02-09 | — | — | US | disclosed |
| EP-1064277-B1 | 2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF INFLAMMATORY CYTOKINES | CELGENE CORP (US) | 2005-06-15 | — | — | EP | disclosed |
| EP-1357120-A1 | 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines | CELGENE CORPORATION (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20030028028-A1 | 1-oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels | CELGENE CORPORATION | 2003-02-06 | — | — | US | disclosed |
| US-6403613-B1 | ANTI-INFLAMMATORY AGENT THAT REDUCES LEVELS OF CYTOKINES (INCLUDING TUMOR NECROSIS FACTOR) | CELGENE CORPORATION | 2002-06-11 | — | — | US | disclosed |
| US-20010006973-A1 | 1-OXO- AND 1,3-DIOXOISOINDOLINES AND METHOD OF REDUCING INFLAMMATORY CYTOKINE LEVELS | MAN HON-WAH (US) | 2001-07-05 | — | — | US | disclosed |
| EP-1064277-A1 | 2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF INFLAMMATORY CYTOKINES | Gelgene Corporation (US) | 2001-01-03 | — | — | EP | disclosed |
| WO-1999047512-A1 | 2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF INFLAMMATORY CYTOKINES | COLGENE CORPORATION (US) | 1999-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030592-A1 | I-Oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels | IL1A, IL1B, TNF | KDR 4114/4885RET 4390/4885CDK8 3620/4885 |
| US-20080287496-A1 | 1-Oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels | IL1A, IL1B, TNF | KDR 4009/4885RET 4441/4885CDK8 3764/4885 |
| US-20060160803-A1 | Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity | MAP3K21, HIPK4, MAP3K20 | KDR 729/4885RET 252/4885CDK8 501/4885 |
| US-20010006973-A1 | 1-OXO- AND 1,3-DIOXOISOINDOLINES AND METHOD OF REDUCING INFLAMMATORY CYTOKINE LEVELS | TNF, IL1A, IL1B | KDR 3998/4885RET 4369/4885CDK8 3741/4885 |
| US-20030028028-A1 | 1-oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels | TNF, IL1A, IL1B | KDR 3998/4885RET 4369/4885CDK8 3741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.